PEPGEN INC (PEPG)

Company Profile

PepGen Inc. develops oligonucleotide therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 45 full-time employees. The company went IPO on 2022-05-06. The firm is engaged in developing a transformative oligonucleotide delivery technology and pipeline of product candidates to treat neuromuscular and neurologic diseases. Its enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. The Company, through its EDO platform, is developing a pipeline of disease-modifying peptide-conjugated oligonucleotide candidates to treat a variety of degenerative neuromuscular diseases. Its lead product candidates include PGN-EDO51 and PGN-EDODM1. Its lead product candidate, PGN-EDO51, is an EDO peptide conjugated to a phosphorodiamidate morpholino oligomer (PMO) therapeutic cargo, which is developed for the treatment of duchenne muscular dystrophy (DMD) patients with mutations amenable to exon 51-skipping approach. The company is also developing PGN-EDODM1, for the treatment of myotonic dystrophy type 1 (DM1).

Company Info

PEPGEN INC

245 Main St, 2nd Floor

Cambridge MASSACHUSETTS

P: 17034568000

Employees: 45

Website: https://pepgen.com